Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
40–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
signed an Informed Consent Form
stable COPD according to current guidelines (GOLD 2013)
airflow limitation indicated by a post-bronchodilator FEV1/FVC ratio of \<0.70 and a post-bronchodilator FEV1 of ≥30% and \<80% of predicted normal values at Visit 2.
current or ex-smokers who have a smoking history of at least 10 pack years
Patients on stable tiotropium (18 µg/d) monotherapy for at least 8 weeks before Visit 1
Symptomatic patients defined as patients with CAT score ≥ 10 at Visit 1 (Screening).
You may not be if
Pregnant or breast feeding mothers
Patients with conditions contraindicated for treatment
Patients with a history of clinically significant diseases
Patients who have a clinically significant renal disease
Patients with myocardial infarctions less than 6 months prior to study entry
Patients with recent (less than 1 year) history of NYHA Class III/IV left ventricular failure.
Patients with narrow-angle glaucoma, symptomatic prostatic hyperplasia or bladder-neck obstruction or urinary retention
Patients with a history of malignancy of any organ system
Patients who have had a COPD exacerbation that required treatment with antibiotics, and/or systemic steroids (oral or intravenous) and/or hospitalization in the 6 weeks prior to Screening
Patients who have had a respiratory tract infection within 6 weeks prior to Screening
Patients with any history of asthma.
Clareo Health | Lung Function and Patient Preference With QVA149 vs. Tiotropium in COPD Patients
